Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also devel… Read more
Astria Therapeutics Inc (ATXS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.138x
Based on the latest financial reports, Astria Therapeutics Inc (ATXS) has a cash flow conversion efficiency ratio of -0.138x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.30 Million) by net assets ($233.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Astria Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Astria Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Astria Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Astria Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Empire State Realty Trust Inc
NYSE:ESRT
|
0.059x |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
0.014x |
|
Sichuan Chuanhuan Technology Co Ltd
SHE:300547
|
-0.006x |
|
Premier Investments Ltd
AU:PMV
|
0.041x |
|
Hyundai Department
KO:069960
|
0.049x |
|
QI7
F:QI7
|
N/A |
|
Tangrenshen Group Co Ltd
SHE:002567
|
0.028x |
|
Amore Group
KO:002790
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Astria Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Astria Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $319.26 Million | $-81.21 Million | -0.254x | +9.65% |
| 2023-12-31 | $243.12 Million | $-68.44 Million | -0.282x | -43.06% |
| 2022-12-31 | $221.22 Million | $-43.53 Million | -0.197x | +20.17% |
| 2021-12-31 | $122.31 Million | $-30.15 Million | -0.247x | +69.14% |
| 2020-12-31 | $40.67 Million | $-32.48 Million | -0.799x | -7.39% |
| 2019-12-31 | $35.72 Million | $-26.57 Million | -0.744x | -10.76% |
| 2018-12-31 | $34.94 Million | $-23.46 Million | -0.672x | +70.49% |
| 2017-12-31 | $11.79 Million | $-26.84 Million | -2.276x | -101.45% |
| 2016-12-31 | $29.09 Million | $-32.86 Million | -1.130x | -91.46% |
| 2015-12-31 | $50.49 Million | $-29.79 Million | -0.590x | -311.17% |
| 2014-12-31 | $-73.05 Million | $-20.41 Million | 0.279x | -10.91% |
| 2013-12-31 | $-52.18 Million | $-16.37 Million | 0.314x | +108.63% |
| 2012-12-31 | $4.29K | $-15.58K | -3.634x | -- |